EGFR and neoplasm: Reported ability of Fus1/Tusc2 to inhibit receptor (EGFR, PDGFR, c-Kit) and non-receptor (c-Abl, Akt) tyrosine kinases as well as promote apoptosis [14] makes Fus1/Tusc2 a promising adjuvant for successful anti-tumor chemotherapy (https://clinicaltrials.gov/ct2/show/NCT01455389, https://clinicaltrials.gov/ct2/show/NCT04486833).